Actively Recruiting
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
Led by IRCCS San Raffaele Roma · Updated on 2025-05-01
500
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The object of this study is to assess the effectiveness, safety, and tolerability of eptinezumab in a real life migraine population.
CONDITIONS
Official Title
EptinezuMaB in ReAl-world evidenCE: Multicenter, Real Life, Cohort Study in Migraine.
Who Can Participate
Eligibility Criteria
You may qualify if you...
KEY INCLUSION CRITERIA
- Age between 18 and 75 years;
- Males and females;
- Willingness to sign the informed consent;
- High frequency episodic migraine, at least 8 days per month of disabling migraine in the past 3 months;
- Chronic migraine, according to the ICHD-III criteria;
KEY EXCLUSION CRITERIA
- Other headaches different than migraine;
- Known intolerance to eptinezumab or eccipients;
- Current treatment with other mAbs;
- Vascular disease or Raynaud.
You will not qualify if you...
History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
IRCCS San Raffaele Roma
Roma, RM, Italy, 00163
Actively Recruiting
Research Team
P
Piero Barbanti, MD, PhD
CONTACT
C
Cinzia Aurilia, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here